IQVIA Holdings Inc. (NYSE:IQV), a prominent figure in the bio-tech market, has been experiencing varying fortunes. Many notable financial entities have either bought or sold considerable shares of the company. For instance,
Mitsubishi UFJ Trust & Banking Corp sold 5,785 shares, and
Empowered Funds LLC bought 658 shares. Meanwhile, FY2024 EPS estimates for the company have been raised by analysts. Despite some underperformances compared to competitors on certain trading days, IQVIA's financial situation seems robust. Share price targets hover around $256.40. Several other investing entities like
SG Americas Securities LLC and
Jennison Associates LLC respectively boosted and purchased stakes in the company. Additionally, FY2024 and Q4 2023 earnings for IQVIA beat estimates, and the firm showed impressive YoY growth in Q4 and Full Year 2023 Earnings. However, certain developments raise concern, such as insiders at IQVIA selling US$9.2m in stock, alluding to potential weakness. The company also trimmed revenue forecasts amid challenges. IQVIA was named a leader in medical affairs and regulatory operations by Everest Group, showing a positive reputation in its field.
Iqvia Holdings IQV News Analytics from Thu, 21 Jul 2022 07:00:00 GMT to Sun, 21 Jul 2024 17:41:26 GMT -
Rating 4
- Innovation 3
- Information 7
- Rumor 2
